Anika Therapeutics Receives 510 (K) FDA Clearance for Injectable Bone Substitute

23 October 2021

1 minute read

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Anika Therapeutics Inc. announced the 510 (k) FDA clearance for Tactoset, an injectable bone substitute designed to increase the attachment of suture anchors, according to a press release from the company.

Tactoset is a calcium phosphate-based bone graft substitute that features a core of hyaluronic acid (HA) for easy injection, according to the release.

“Pulling out poor quality bones and suture anchors is a real problem for patients in our industry, and surgeons can now use Tactoset to increase suture anchor fixation and strengthen it. inside the bone. We have taken our improved proprietary HA Tactoset and opened up an untapped market in augmenting hardware including soft tissue suture anchors ”, Ben Joseph, vice president of US commercial and global brand management at Anika Therapeutics, said in the statement. “Tactoset is a key growth driver within our current regenerative solutions portfolio, and this increase approval highlights Anika’s transformation as a joint preservation and restoration venture. We have big plans for Tactoset in the market and we expect to have additional indications in the future, ”added Joseph.

Comments are closed.